RedHill Biopharma Ltd. [RDHL] stock Initiated by Cantor Fitzgerald analyst, price target now $22

Related

RedHill Biopharma Ltd. [NASDAQ: RDHL] surged by $0.2 during the normal trading session on Monday and reaching a high of $1.03 during the day while it closed the day at $1.02. The company report on June 23, 2022 that RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Targeting positive cash from operations to start during H2/22[1].

Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months.

RedHill Biopharma Ltd. stock has also gained 60.38% of its value over the past 7 days. However, RDHL stock has declined by -63.57% in the 3 months of the year. Over the past six months meanwhile, it has lost -61.36% and lost -60.47% year-on date.

The market cap for RDHL stock reached $50.88 million, with 52.52 million shares outstanding and 34.99 million shares in the current float. Compared to the average trading volume of 1.70M shares, RDHL reached a trading volume of 11753141 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about RedHill Biopharma Ltd. [RDHL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RDHL shares is $12.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RDHL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for RedHill Biopharma Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 31, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 18, 2021, representing the official price target for RedHill Biopharma Ltd. stock.

The Average True Range (ATR) for RedHill Biopharma Ltd. is set at 0.12, with the Price to Sales ratio for RDHL stock in the period of the last 12 months amounting to 0.59.

RDHL stock trade performance evaluation

RedHill Biopharma Ltd. [RDHL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 60.38. With this latest performance, RDHL shares gained by 6.46% in over the last four-week period, additionally sinking by -61.36% over the last 6 months – not to mention a drop of -85.37% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RDHL stock in for the last two-week period is set at 53.84, with the RSI for the last a single of trading hit 65.59, and the three-weeks RSI is set at 47.03 for RedHill Biopharma Ltd. [RDHL]. The present Moving Average for the last 50 days of trading for this stock 1.2269, while it was recorded at 0.8101 for the last single week of trading, and 2.8174 for the last 200 days.

RedHill Biopharma Ltd. [RDHL]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and RedHill Biopharma Ltd. [RDHL] shares currently have an operating margin of -94.61 and a Gross Margin at +42.39. RedHill Biopharma Ltd.’s Net Margin is presently recorded at -113.98.

Return on Equity for this stock declined to -860.29, with Return on Assets sitting at -54.12.

RedHill Biopharma Ltd. [RDHL]: Insider Ownership positions

There are presently around $4 million, or 13.00% of RDHL stock, in the hands of institutional investors. The top three institutional holders of RDHL stocks are: DISCIPLINED GROWTH INVESTORS INC /MN with ownership of 1,950,002, which is approximately 0.745% of the company’s market cap and around 12.96% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 861,798 shares of the stock with an approximate value of $0.71 million in RDHL stocks shares; and GAGNON SECURITIES LLC, currently with $0.3 million in RDHL stock with ownership of nearly 15.4% of the company’s market capitalization.

Positions in RedHill Biopharma Ltd. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 14 institutional holders increased their position in RedHill Biopharma Ltd. [NASDAQ:RDHL] by around 1,049,912 shares. Additionally, 26 investors decreased positions by around 1,180,585 shares, while 18 investors held positions by with 2,436,500 shares. The mentioned changes placed institutional holdings at 4,666,997 shares, according to the latest SEC report filing. RDHL stock had 2 new institutional investments in for a total of 888,662 shares, while 10 institutional investors sold positions of 819,104 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]